nyuuzyou/wikis huggingface dataset:
Omacetaxine (Synribo)

==General information==
Class/mechanism: Cephalotaxine ester & natural alkaloid that inhibits protein synthesis/translation/elongation; prepared via a semi-synthetic process from cephalotaxine, an extract of Cephalotaxus species leaves. Mechanism is not fully understood, but omacetaxine mepesuccinate inhibits protein synthesis and promotes apoptosis in a manner that does not involve direct binding of Bcr-Abl. Omacetaxine mepesuccinate has been observed to bind to the A-site cleft in the large ribosomal subunit of a type of archaeabacteria. It reduces levels of Bcr-Abl and human induced myeloid leukemia cell differentiation protein Mcl-1, an anti-apoptotic Bcl-2 family member. Omacetaxine mepesuccinate has been seen to have activity in mouse models with wild-type Bcr-Abl, as well as imatinib-resistant chronic myeloid leukemia (CML) models with the T315I mutation.Omacetaxine mepesuccinate (Synribo) package insert Omacetaxine mepesuccinate (Synribo) package insert (locally hosted backup)Synribo manufacturer's websiteQuintás-Cardama A, Kantarjian H, Cortes J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer. 2009 Dec 1;115(23):5382-93. link to original article EuroPMC
Route: IV, SC
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is used==
*Acute myeloid leukemia
*Chronic myeloid leukemia
==Patient drug information==
*Omacetaxine (Synribo) package insert
*Omacetaxine (Synribo) patient drug information (Chemocare)Omacetaxine (Synribo) patient drug information (Chemocare)
*Omacetaxine (Synribo) patient drug information (UpToDate)Omacetaxine (Synribo) patient drug information (UpToDate)
==History of changes in FDA indication==
*2012-10-26: Accelerated approval for treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI). (Based on CGX-635-CML-202 and CGX-635-CML-203)
**2014-02-10: Converted to regular approval for treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI). (Based on CGX-635-CML-202 and CGX-635-CML-203)
==Also known as==
*Generic names: HHT, homoharringtonine, omacetaxine mepesuccinate
*Brand names: Omapro, Synribo
==References==
Category:Drugs
Category:Intravenous medications
Category:Subcutaneous medications
Category:Cephalotaxine
Category:Acute myeloid leukemia medications
Category:Chronic myeloid leukemia medications
Category:FDA approved in 2012
Onartuzumab (MetMAb)

==General information==
Class/mechanism: Monovalent (one-armed) monoclonal antibody that binds to the extracellular Sema domain of c-Met and inhibits binding of hepatocyte growth factor (HGF). This interferes with ligand-dependent c-Met dimerization, activation of the intracellular kinase domain, and downstream signals that normally promote tumor proliferation, survival, and metastasis. The monovalent design was chosen to avoid potentially activating Met through dimerization of two Met molecules by onartuzumab.Genentech's Onartuzumab/MetMab site
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the package insert.
==Patient drug information==
No information available.
==Also known as==
*Code names: MetMAb, RO5490258
==References==
Category:Drugs
Category:Intravenous medications
Category:Anti-c-Met antibodies
Category:Investigational drugs
Ondansetron (Zofran)

==General information==
Class/mechanism: Selective serotonin 5-HT3 receptor antagonist. Chemotherapy medications can cause nausea and vomiting by stimulating release of serotonin from the enterochromaffin cells of the small intestine, and serotonin triggers the vomiting reflex by binding to and activating 5-HT3 receptors. Ondansetron prevents nausea and vomiting by binding with high affinity to 5-HT3 receptors and blocking their activation by serotonin.Ondansetron (Zofran) package insert Ondansetron (Zofran) package insert (locally hosted backup)
Route: PO, IV
Extravasation: no information available
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Patient drug information==
*Patient counseling information can be found in the Ondansetron (Zofran) package insert
*Ondansetron (Zofran) patient drug information (UpToDate)Ondansetron (Zofran) patient drug information (UpToDate)
==History of changes in FDA indication==
* 1991-01-04: Initial FDA approval
==Also known as==
*Code name: SN-307
*Brand names:
Synonyms 	Synonyms 	Synonyms 	Synonyms 	Synonyms 	Synonyms 	Synonyms 	Synonyms
Alencar 	Amilene 	Ansentron	Anset 	Atossa 	Bryterol 	Cedantron	Ceramos
Danofran 	Dantenk 	Emeran 	Emeset 	Emetra 	Emetron 	Emigo 	Emistat
Emivox 	Espasevit	Finaber 	Finoxi 	Frazon 	Glendan 	Helmine 	Injectrax
Insetron 	Invomit 	Izofran 	Latran 	Modifical	Narfoz 	Nausedron	Nautah
Neomit 	Nuset 	O.N.D. 	Odanex 	Odanse 	Ometic 	Omstron 	Onaset
Oncotor 	Onda 	Ondace 	Ondan 	Ondanles 	Ondansetron-Z	Ondant 	Ondaren
Ondasetron	Ondatie 	Ondavell 	Ondem 	Ondemet 	Onfran 	Onilat 	Onsat
Onseran 	Onset 	Onsetron 	Onsett 	Onsia 	Ontrax 	Onzod 	Osetron
Ostasyn 	Otobrol 	Periset 	Quimiofran	Seton 	Setronax 	Setronon 	Sopran
Trorix 	Vomceran 	Vomiban 	Vomigo 	Vomikind 	Vomiset 	Vomitron 	Vomiz
Vonau 	Yatrox 	Zantron 	Zapron 	Zemitron 	Zofer 	Zofran 	Zofran ODT
Zofron 	Zoltem 	Zonax 	Zondan 	Zophren 	Zudan 	Zuplenz 	
==References==
* Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med. 2000 May 25;342(21):1554-9. link to original article EuroPMC
Category:Drugs
Category:Oral medications
Category:Intravenous medications
Category:Emesis prevention
Category:Serotonin 5-HT3 antagonists
Category:FDA approved in 1991
Category:WHO Essential Pain and Palliative Care Medicine
Opioid Conversion Table

Note: There are disagreements about the accuracy of these conversions, which were mostly established in healthy persons. If and when guidelines on this topic are available regarding cancer-related pain, we will add them here.
=Morphine milligram equivalent (MME)=
*Oral morphine: 1 MME
*Hydrocodone: 1 MME
*Oxycodone: 1.5 MME
*IV morphine: 3 MME
*Oral hydromorphone: 4 MME
*IV hydromorphone: 20 MME
=Conversion table using common doses=
Opioid 	IV/SubQ/IM (mg)	PO/Rectal (mg)
Morphine 	10 	30
Hydrocodone 	- 	30
Oxycodone 	- 	20
Hydromorphone	1.5 	7.5
Codeine 	- 	200
Hydrocodone 	- 	30
Tramadol 	- 	100
Fentanyl* 	0.1 	-
*Fentanyl dosing is only for intermittent bolus dosing. 
To convert Fentanyl boluses to Fentanyl patch, please see example opioid conversions.
===Morphine : Methadone have a dose based adjustment===
Up to 100 mg/day Morphine --> 4:1 of Methadone
101-300 mg/day Morphine --> 8:1 of Methadone 
301-500 mg/day Morphine --> 12:1 of Methadone 
501-1000 mg/day Morphine --> 15:1 of Methadone
>1001mg/day Morphine --> 20:1 of Methadone
Category:General reference pages
Category:Clinical pharmacology
Oprelvekin (Neumega)

==Mechanism of action==
Synthetic version of IL-11, a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. 
==History of changes in FDA indication==
*1997-11-25: Initial FDA approval (no label available on Drugs @ FDA)
*2002-09-18: Label indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia.
==Also known as==
*Brand name: Neumega
Category:Drugs
Category:Subcutaneous medications
Category:Hematopoietic growth factors
Category:Megakaryocyte growth factors
Category:FDA approved in 1997
Oprozomib (ONX-0912)

==Mechanism of action==
From NCI drug dictionary: An orally bioavailable proteasome inhibitor with potential antineoplastic activity. Oprozomib inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and inhibition of tumor growth. 
==Preliminary data==
===Multiple myeloma===
# Abstract: Ravi Vij, MBBS, MD, Michael Savona, MD, David S. Siegel, MD, PhD, Jonathan L. Kaufman, MD, Ashraf Badros, MD, Irene M. Ghobrial, MD, Agne Paner, MD, Sundar Jagannath, MD, Andrzej Jakubowiak, MD, PhD, Joseph R. Mikhael, MD, Prashant Kapoor, MD, Linda L. Neuman, MD, MBA, Ju RueyJiuan Lee, PhD and Jesus G. Berdeja, MD. Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study. ASH 2014 Abstract 34 link to abstract
# Abstract: Parameswaran N. Hari, MD, Kenneth H. Shain, MD, PhD, Peter M. Voorhees, MD, Nashat Gabrail, MD, Muneer H. Abidi, MD, Jeffrey Zonder, MD, Ralph V. Boccia, MD, Paul G. Richardson, Linda L. Neuman, MD, MBA, Sandra J. Dixon, MS and Claudia Paba Prada, MD. Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study. ASH 2014 Abstract 3453 link to abstract
==Also known as==
*Code name: ONX-0912
Category:Drugs
Category:Oral medications
Category:Proteasome inhibitors
Category:Multiple myeloma medications (investigational)
Category:Investigational drugs
Orteronel (TAK-700)

==General information==
Class/mechanism: Antiandrogen, androgen biosynthesis inhibitor, CYP17 inhibitor. Inhibits the 17 α-hydroxylase/C17,20-lyase (CYP17) enzyme that is required for androgen biosynthesis, leading to a decrease in androgen production in testicular, adrenal, and prostate tumor tissues.TAK-700 information (NCI drug dictionary)
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Prostate cancer===
#SWOG S1216: Agarwal N, Tangen CM, Hussain MHA, Gupta S, Plets M, Lara PN, Harzstark AL, Twardowski PW, Paller CJ, Zylla D, Zibelman MR, Levine E, Roth BJ, Goldkorn A, Vaena DA, Kohli M, Crispino T, Vogelzang NJ, Thompson IM Jr, Quinn DI. Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). J Clin Oncol. 2022 Oct 1;40(28):3301-3309. Epub 2022 Apr 21. link to original article link to PMC article EuroPMC NCT01809691
##Subgroup analysis: Sayegh N, Swami U, Jo Y, Gebrael G, Haaland B, Gupta S, Plets M, Hussain MHA, Quinn DI, Lara PN Jr, Thompson IM Jr, Agarwal N. Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial. JAMA Netw Open. 2023 Aug 1;6(8):e2326546. link to original article link to PMC article EuroPMC
==Also known as==
*Code name: TAK-700
==References==
Category:Drugs
Category:Oral medications
Category:CYP17 inhibitors
Category:Prostate cancer medications (investigational)
Category:Halted drugs
Osocimab (BAY-1213790)

==Mechanism of action==
Anti-Factor XIa antibody
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Venous thromboembolism===
# FOXTROT: Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, Metzig C, Raskob GE. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020 Jan 14;323(2):130-139. link to original article link to PMC article EuroPMC
==Also known as==
*Code name: BAY-1213790
Category:Drugs
Category:Intravenous medications
Category:Anti-Factor XIa antibodies
Category:Venous thromboembolism medications (investigational)
Category:Investigational drugs
Otlertuzumab (TRU-016)

==Mechanism of action==
Anti-CD37 antibody. CD37 is a cell surface tetraspanin.
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Chronic lymphocytic leukemia===
# Aptevo 16201: Robak T, Hellmann A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel JM, Mato A, Byrd JC, Awan FT, Hebart H, Garcia-Marco JA, Hill BT, Hallek M, Eisenfeld AJ, Stromatt SC, Jaeger U. Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2017 Feb;176(4):618-628. Epub 2016 Dec 15. link to original article link to PMC article EuroPMC NCT01188681
==Also known as==
*Code name: TRU-016
Category:Drugs
Category:Intravenous medications
Category:Anti-CD37 antibodies
Category:Chronic lymphocytic leukemia medications (investigational)
Category:Investigational drugs
P-glycoprotein modifying drugs

=P-glycoprotein substrates=
*Colchicine
*Cyclosporine
*Digoxin
*Fexofenadine
*Indinavir
*Morphine
*Sirolimus (Rapamune)
=P-glycoprotein inhibitors=
*Amiodarone
*Clarithromycin (Biaxin)
*Erythromycin
*Ketoconazole (Nizoral)
*Quinidine
*Saquinivir
*Verapimil
=P-glycoprotein inducers=
*Carbamazepine
*Rifampin
*St. John's wort
*Tipranavir
Category:General reference pages
Category:Clinical pharmacology
PEComa

Back to Top
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
Last updated on 2024-07-23:1 regimens on this page
1 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==NCCN==
*NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Soft Tissue Sarcoma.
=All lines of therapy=
==nab-Sirolimus monotherapy==
===Regimen===
FDA-recommended dose
Study 	Dates of enrollment	Evidence
Wagner et al. 2021 (AMPECT)	2016-2018 	Phase 2 (RT)
====Targeted therapy====
*Sirolimus protein-bound particles (Fyarro) 100 mg/m2 IV once per day on days 1 & 8
21-day cycles
===References===
# AMPECT: Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Grigorian B, Schmid AN, Hou S, Harris K, Kwiatkowski DJ, Desai NP, Dickson MA. nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. J Clin Oncol. 2021 Nov 20;39(33):3660-3670. Epub 2021 Oct 12. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT02494570
##Update: Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Ding L, Schmid AN, Navarro WH, Kwiatkowski DJ, Dickson MA. Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update. J Clin Oncol. 2024 May 1;42(13):1472-1476. Epub 2024 Mar 1. link to original article link to PMC article EuroPMC
Category:PEComa regimens
Category:Disease-specific pages
Category:Soft tissue sarcomas
PJP Prophylaxis

The purpose of this page is to list the various types of PJP prophylaxis in common usage.
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==Consensus guidelines==
*2017: Proudfoot et al. Guidelines for the Prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in Children With Solid Tumors EuroPMC
*2014: Cooley et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014 EuroPMC
=Prophylaxis=
===Trimethoprim-Sulfamethoxazole===
===Atovaquone (Mepron)===
===Dapsone (Aczone)===
===Pentamidine (Nebupent)===
2023: Incidence of Pneumocystis Pneumonia in Immunocompromised Patients without Human Immunodeficiency Virus on Intravenous Pentamidine Prophylaxis: A Systematic Review and Meta-Analysis EuroPMC
=Treatment=
To be completed
Category:Supportive oncology
POEMS syndrome

Back to Top
POEMS: Peripheral neuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma cell disorder, and Skin changes
Last updated on 2024-07-23:1 regimens on this page
1 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==EMN==
*2018: Gavriatopoulou et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias EuroPMC
=All lines of therapy=
==Lenalidomide & Dexamethasone (Rd)==
Rd: Revlimid (Lenalidomide) & low-dose dexamethasone
===Regimen===
Study 	Dates of enrollment	Evidence
Nozza et al. 2017	2009-10 to 2014-10 	Phase 2, fewer than 20 pts
====Targeted therapy====
*Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
====Glucocorticoid therapy====
*Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15, 22
====Supportive therapy====
*Aspirin 100 mg PO once per day
**LMWH in "intolerant" patients
*Cotrimoxazole 800 mg PO twice per day two days per week
28-day cycle for at least 6 cycles
===References===
# Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC EudraCT 2008-003202-33
Category:POEMS syndrome regimens
Category:Disease-specific pages
Category:Plasma cell dyscrasias
Pacritinib (Vonjo)

==Mechanism of action==
From the NCI Drug Dictionary: An orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis. Also, per Hart et al. 2011 pacritinib is a tyrosine kinase inhibitor (TKI) with equipotent activity against FLT3 (IC50=22 n) and Janus kinase 2 (JAK2, IC50=23 n). 
==Diseases for which it is used==
*Myelofibrosis
==History of changes in FDA indication==
*2022-03-01: Granted accelerated approval for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 109/L. (Based on PERSIST-2)
==Also known as==
*Code name: SB-1518
*Brand name: Vonjo
Category:Drugs
Category:Oral medications
Category:FLT3 inhibitors
Category:JAK2 inhibitors
Category:Myelofibrosis medications
Category:FDA approved in 2022
Palifermin (Kepivance)

==General information==
From the NCI Drug Dictionary: A recombinant form of the endogenous human keratinocyte growth factor. Palifermin binds to epithelial cell surface receptors in the lining of the mouth and gastrointestinal tract, resulting in stimulation of epithelial cell proliferation, differentiation and upregulation of cytoprotective mechanisms.
==Also known as==
*Generic name: rhKGF
*Brand name: Kepivance
Category:Drugs
Category:Intravenous medications
Category:Keratinocyte growth factors
Category:Chemotherapy protective agents
Category:Mucositis prevention
Category:Recombinant medications
Category:FDA approved in 2004
Palliative Care

=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==ASCO==
*2024: Sanders et al. Palliative Care for Patients With Cancer: ASCO Guideline Update EuroPMC
**2017: Ferrell et al. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update EuroPMC
**2011: Smith et al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care EuroPMC
==ESMO==
*2014: Schrijvers & Cherny. ESMO Clinical Practice Guidelines on palliative care: advanced care planning EuroPMC
*2014: Cherny. ESMO Clinical Practice Guidelines for the management of refractory symptoms at the end of life and the use of palliative sedation EuroPMC
==NCCN==
*2009: Levy et al. NCCN clinical practice guidelines in oncology: palliative care. EuroPMC
=General reference=
==These are some topics that you may find helpful relating to palliative medicine.== 
*Top 10 facts about advanced directives
*Top 10 facts oncologists should know about palliative medicine
*Pain Assessment
*Basics of Pain Management
*Opioid Conversion Table
*Serious Illness Conversation Guide 
*Interesting studies involving palliative medicine in oncology patients
Category:Supportive oncology